tetano
Editor, Senior Moderator
Vaccine. 2016 Oct 25. pii: S0264-410X(16)30975-6. doi: 10.1016/j.vaccine.2016.10.040. [Epub ahead of print]
[h=1]Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project.[/h] Liu H[SUP]1[/SUP], Frijlink HW[SUP]2[/SUP], Huckriede A[SUP]3[/SUP], van Doorn E[SUP]4[/SUP], Schmidt E[SUP]2[/SUP], Leroy O[SUP]5[/SUP], Rimmelzwaan G[SUP]6[/SUP], McCullough K[SUP]7[/SUP], Whelan M[SUP]8[/SUP], Hak E[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Due to influenza viruses continuously displaying antigenic variation, current seasonal influenza vaccines must be updated annually to include the latest predicted strains. Despite all the efforts put into vaccine strain selection, vaccine production, testing, and administration, the protective efficacy of seasonal influenza vaccines is greatly reduced when predicted vaccine strains antigenically mismatch with the actual circulating strains. Moreover, preparing for a pandemic outbreak is a challenge, because it is unpredictable which strain will cause the next pandemic. The European Commission has funded five consortia on influenza vaccine development under the Seventh Framework Programme for Research and Technological Development (FP7) in 2013. The call of the EU aimed at developing broadly protective influenza vaccines. Here we review the scientific strategies used by the different consortia with respect to antigen selection, vaccine delivery system, and formulation. The issues related to the development of novel influenza vaccines are discussed.
Copyright ? 2016. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Broadly protective; Correlates of protection; EU consortia; Influenza; Vaccines
PMID: 27793486 DOI: 10.1016/j.vaccine.2016.10.040
[PubMed - as supplied by publisher]
[h=1]Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project.[/h] Liu H[SUP]1[/SUP], Frijlink HW[SUP]2[/SUP], Huckriede A[SUP]3[/SUP], van Doorn E[SUP]4[/SUP], Schmidt E[SUP]2[/SUP], Leroy O[SUP]5[/SUP], Rimmelzwaan G[SUP]6[/SUP], McCullough K[SUP]7[/SUP], Whelan M[SUP]8[/SUP], Hak E[SUP]9[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Due to influenza viruses continuously displaying antigenic variation, current seasonal influenza vaccines must be updated annually to include the latest predicted strains. Despite all the efforts put into vaccine strain selection, vaccine production, testing, and administration, the protective efficacy of seasonal influenza vaccines is greatly reduced when predicted vaccine strains antigenically mismatch with the actual circulating strains. Moreover, preparing for a pandemic outbreak is a challenge, because it is unpredictable which strain will cause the next pandemic. The European Commission has funded five consortia on influenza vaccine development under the Seventh Framework Programme for Research and Technological Development (FP7) in 2013. The call of the EU aimed at developing broadly protective influenza vaccines. Here we review the scientific strategies used by the different consortia with respect to antigen selection, vaccine delivery system, and formulation. The issues related to the development of novel influenza vaccines are discussed.
Copyright ? 2016. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Broadly protective; Correlates of protection; EU consortia; Influenza; Vaccines
PMID: 27793486 DOI: 10.1016/j.vaccine.2016.10.040
[PubMed - as supplied by publisher]